Zimmer Biomet Holdings, Inc. $ZBH Position Trimmed by Heritage Investors Management Corp

Heritage Investors Management Corp decreased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 5.2% during the third quarter, HoldingsChannel.com reports. The fund owned 113,823 shares of the medical equipment provider’s stock after selling 6,235 shares during the quarter. Heritage Investors Management Corp’s holdings in Zimmer Biomet were worth $10,111,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Zimmer Biomet during the 3rd quarter valued at approximately $4,628,000. ProShare Advisors LLC raised its stake in Zimmer Biomet by 11.5% during the third quarter. ProShare Advisors LLC now owns 41,337 shares of the medical equipment provider’s stock valued at $3,672,000 after purchasing an additional 4,249 shares in the last quarter. Vise Technologies Inc. purchased a new stake in Zimmer Biomet during the third quarter valued at $268,000. Grandfield & Dodd LLC lifted its position in Zimmer Biomet by 80.5% during the third quarter. Grandfield & Dodd LLC now owns 20,823 shares of the medical equipment provider’s stock valued at $1,818,000 after purchasing an additional 9,284 shares during the last quarter. Finally, Cidel Asset Management Inc. bought a new position in Zimmer Biomet during the third quarter valued at $207,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Stock Up 0.0%

Shares of NYSE:ZBH opened at $94.54 on Monday. Zimmer Biomet Holdings, Inc. has a 1 year low of $79.12 and a 1 year high of $103.70. The business has a 50 day simple moving average of $94.86 and a two-hundred day simple moving average of $91.70. The firm has a market capitalization of $18.03 billion, a PE ratio of 23.00, a price-to-earnings-growth ratio of 2.27 and a beta of 0.49. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.69 and a quick ratio of 0.94.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, beating analysts’ consensus estimates of $2.01 by $0.06. Zimmer Biomet had a return on equity of 13.12% and a net margin of 9.48%. The firm had revenue of $2.18 billion for the quarter, compared to analysts’ expectations of $2.13 billion. During the same quarter in the prior year, the firm posted $2.07 earnings per share. The company’s quarterly revenue was up 4.8% on a year-over-year basis. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. On average, equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.54 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th were given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. The ex-dividend date was Wednesday, September 30th. Zimmer Biomet’s dividend payout ratio (DPR) is 23.36%.

Wall Street Analysts Forecast Growth

ZBH has been the topic of a number of research reports. Truist Financial boosted their target price on shares of Zimmer Biomet from $92.00 to $106.00 and gave the stock a “hold” rating in a report on Thursday, August 6th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Zimmer Biomet in a report on Monday, September 28th. Zacks Research upgraded Zimmer Biomet from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 25th. Citigroup restated a “neutral” rating on shares of Zimmer Biomet in a research report on Monday, October 5th. Finally, Robert W. Baird set a $104.00 price objective on Zimmer Biomet in a research note on Thursday, August 6th. Seven research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Zimmer Biomet presently has a consensus rating of “Hold” and a consensus price target of $104.47.

Insiders Place Their Bets

In other news, insider Kevin R. Thornal sold 5,691 shares of the business’s stock in a transaction on Friday, September 11th. The shares were sold at an average price of $92.95, for a total transaction of $528,978.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Chad Phipps sold 3,000 shares of the company’s stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $98.35, for a total transaction of $295,050.00. Following the completion of the transaction, the insider owned 65,231 shares in the company, valued at approximately $6,415,468.85. The trade was a 4.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 1.28% of the stock is currently owned by insiders.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc is a medical technology company that develops and manufactures products used in orthopedic surgery and musculoskeletal care. Its portfolio includes implants for the hip, knee, shoulder, and other joints, as well as products for sports medicine, extremity reconstruction, trauma, and spine procedures.

The company also offers surgical technologies and solutions designed to support orthopedic procedures, including robotic-assisted surgery systems, digital tools, patient-specific planning, and related instruments.